Toggle Main Menu Toggle Search

Open Access padlockePrints

Do cervical cancer data justify HPV vaccination in India? Epidemiological data sources and comprehensiveness

Lookup NU author(s): Professor Allyson Pollock, Dr Petra Sevcikova

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

The Indian government suspended research in April 2010 on the feasibility and safety of human papillomavirus (HPV) vaccine in two Indian states (Andhra Pradesh and Gujarat) amid public concerns about its safety. This paper describes cervical cancer and cancer surveillance in India and reviews the epidemiological claims made by the Programme for Appropriate Technology in Health (PATH) in support of the vaccine in these two states. National cancer data published by the Indian National Cancer Registry Programme of state registry returns and the International Agency for Research on Cancer cover around seven percent of the population with underrepresentation of rural, northern, eastern and north-eastern areas. There is no cancer registry in the state of Andhra Pradesh and PATH does not cite data from the Gujarat cancer registries. Age-adjusted cervical cancer mortality and incidence rates vary widely across and within states. National trends in age standardized cervical cancer incidence fell from 42.3 to 22.3 per 100,000 between 1982/1983 and 2004/2005 respectively. Incidence studies report low incidence and mortality rates in Gujarat and Andhra Pradesh. Although HPV prevalence is higher in cancer patients (93.3%) than healthy patients (7.0%) and HPV types 16 and 18 are most prevalent in cancer patients, population prevelance data are poor and studies highly variable in their findings. Current data on HPV type and cervical cancer incidence do not support PATH's claim that India has a large burden of cervical cancer or its decision to roll out the vaccine programme. In the absence of comprehensive cancer surveillance, World Health Organization criteria with respect to monitoring effectiveness of the vaccine and knowledge of disease trends cannot be fulfilled. © 2012, The Royal Society of Medicine. All rights reserved.


Publication metadata

Author(s): Mattheij I, Pollock AM, Brhlikova P

Publication type: Review

Publication status: Published

Journal: Journal of the Royal Society of Medicine

Year: 2012

Volume: 105

Issue: 6

Pages: 250-262

Print publication date: 01/06/2012

Online publication date: 20/06/2012

ISSN (print): 0141-0768

ISSN (electronic): 1758-1095

URL: https://doi.org/10.1258/jrsm.2012.110343

DOI: 10.1258/jrsm.2012.110343

PubMed id: 22722970


Actions

Find at Newcastle University icon    Link to this publication


Share